Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
Sonya Park(The Catholic University of Korea Seoul St. Mary's Hospital), Erik Mittra(Moffitt Cancer Center), Lisa Bodei(European Institute of Oncology), Ashwin Singh Parihar(Mallinckrodt (United States)), Katherine Zukotynski(Unknown), Nadine Mallak(Oregon Health & Science University), Thomas A. Hope(Fondazione IRCCS Istituto Nazionale dei Tumori), Kalpna Prasad(Walter Reed National Military Medical Center), Don Wilson(University of British Columbia), Corina Millo(National Institutes of Health Clinical Center)
Cited by 71
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
|European Journal of Nuclear Medicine and Molecular Imaging|2014|465